EDIT News and Press, Editas Medicine Inc. From 08/28/23

Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella’s appointment demonstrates Medicenna’s continuing commitment to establish its presence in Boston, ...

2023-08-24 15:42:35 ET More on bluebird bio, CRISPR, etc. Vertex Pharmaceuticals Still Looks Attractive Vertex: Continued Advances In Cystic Fibrosis Market With Expansion Plans Vertex Pharmaceuticals: Strategically Positioning For Future Success Vertex And C...

2023-08-23 08:25:00 ET Unprofitable clinical-stage biotechs have lost their appeal in the past year, given the challenging economic and market conditions we still haven't entirely left behind. That's why companies such as Editas Medicine (NASDAQ: EDIT) and Intellia Therapeutics ...

2023-08-02 07:07:50 ET Editas Medicine press release ( NASDAQ: EDIT ): Q2 GAAP EPS of -$0.56 beats by $0.21 . Revenue of $2.89M (-54.6% Y/Y) misses by $1.5M . Cash, cash equivalents, and marketable securities as of June 30, 2023, were $480.0 million compared to...

On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end Commenced parallel patient dosing in the EDIT-301 EDITHAL trial for TDT and on track to provide a clinical update by year-end Strengthened Executive Team with Appointm...

2023-08-01 12:56:07 ET Editas Medicine ( NASDAQ: EDIT ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is -$0.77 (vs. -$0.78 last year) and the consensus Revenue Estimate is $4.39M (-31.0% Y/Y). Ove...

Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization PR Newswire CAMBRIDGE, Mass. , and DEVENS, Mass. , July 27, 2023 /PRNewswire/ -- Edi...

CAMBRIDGE, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 2, 2023, at 8:00 a.m. ET to discuss results for the second quarter...

CAMBRIDGE, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Scientific Officer, Linda C. Burkly, Ph.D. In connection with...

CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas&...